Cogent Biosciences Inc (NASDAQ:COGT) — Market Cap & Net Worth
Market Cap & Net Worth: Cogent Biosciences Inc (COGT)
Cogent Biosciences Inc (NASDAQ:COGT) has a market capitalization of $5.37 Billion ($5.37 Billion) as of June 17, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #3450 globally and #1201 in its home market, demonstrating a 6.13% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Cogent Biosciences Inc's stock price $33.07 by its total outstanding shares 162308820 (162.31 Million). Review Cogent Biosciences Inc total liabilities to assess the company's total debt and financial obligations.
Cogent Biosciences Inc Market Cap History: 2018 to 2026
Cogent Biosciences Inc's market capitalization history from 2018 to 2026. Data shows change from $2.86 Billion to $5.37 Billion (-3.53% CAGR).
Index Memberships
Cogent Biosciences Inc is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.43 Trillion | 0.22% | #80 of 976 |
|
NASDAQ Composite
IXIC
|
$41.27 Trillion | 0.01% | #385 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.70 Trillion | 0.32% | #53 of 263 |
Weight: Cogent Biosciences Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Cogent Biosciences Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Cogent Biosciences Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
231.58x
Cogent Biosciences Inc's market cap is 231.58 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2018 | $2.86 Billion | $9.73 Million | -$34.53 Million | 293.47x | N/A |
| 2019 | $467.58 Million | $22.50 Million | -$30.27 Million | 20.78x | N/A |
| 2020 | $1.82 Billion | $7.87 Million | -$74.81 Million | 231.58x | N/A |
Competitor Companies of COGT by Market Capitalization
Companies near Cogent Biosciences Inc in the global market cap rankings as of June 17, 2026.
Key companies related to Cogent Biosciences Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #222 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #442 globally with a market cap of $63.33 Billion USD.
- UCB SA (BR:UCB): Ranked #550 globally with a market cap of $49.68 Billion USD ( €42.50 Billion EUR).
- Argen-X (BR:ARGX): Ranked #574 globally with a market cap of $47.14 Billion USD ( €40.32 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #222 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $453.17 |
| #442 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $63.33 Billion | $614.73 |
| #550 | UCB SA | BR:UCB | $49.68 Billion | €250.00 |
| #574 | Argen-X | BR:ARGX | $47.14 Billion | €755.80 |
Cogent Biosciences Inc Historical Marketcap From 2018 to 2026
Between 2018 and today, Cogent Biosciences Inc's market cap moved from $2.86 Billion to $ 5.37 Billion, with a yearly change of -3.53%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $5.37 Billion | -6.90% |
| 2025 | $5.77 Billion | +355.38% |
| 2024 | $1.27 Billion | +32.65% |
| 2023 | $954.38 Million | -49.13% |
| 2022 | $1.88 Billion | +34.73% |
| 2021 | $1.39 Billion | -23.60% |
| 2020 | $1.82 Billion | +289.82% |
| 2019 | $467.58 Million | -83.63% |
| 2018 | $2.86 Billion | -- |
End of Day Market Cap According to Different Sources
On Jun 17th, 2026 the market cap of Cogent Biosciences Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $5.37 Billion USD |
| MoneyControl | $5.37 Billion USD |
| MarketWatch | $5.37 Billion USD |
| marketcap.company | $5.37 Billion USD |
| Reuters | $5.37 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Cogent Biosciences Inc
Cogent Biosciences, Inc., a clinical-stage biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor in Phase 3 trial designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V mutation that drives systemic mastocytosis, as well… Read more